The mammalian Target of Rapamycin (mTOR)-mediated signaling transduction pathway has been observed to be deregulated in a wide variety of cancer and metabolic diseases. Despite extensive clinical development efforts, the well-known allosteric mTOR inhibitor rapamycin and structurally related rapalogs have failed to show significant single-agent antitumor efficacy in most types of cancer. This limited clinical success may be due to the inability of the rapalogs to maintain a complete blockade mTOR-mediated signaling. Therefore, numerous efforts have been initiated to develop ATP-competitive mTOR inhibitors that would block both mTORC1 and mTORC2 complex activity. Here, we describe our experimental approaches to develop Torin1 using a medium throughput cell-based screening assay and structure-guided drug design.
CITATION STYLE
Liu, Q., Kang, S. A., Thoreen, C. C., Hur, W., Wang, J., Chang, J. W., … Gray, N. S. (2012). Development of ATP-competitive mTOR inhibitors. Methods in Molecular Biology, 821, 447–460. https://doi.org/10.1007/978-1-61779-430-8_29
Mendeley helps you to discover research relevant for your work.